Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A known ✓ | P35498 | 3/20 | 1.00 |
| ▸ | SCN2A known ✓ | Q99250 | 3/20 | 1.00 |
| ▸ | SCN3A known ✓ | Q9NY46 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 11/20 | 1.00 |
| ▸ | TP53 | P04637 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 6/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 3/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | GMNN | O75496 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 9/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.97 |
| ▸ | THPO | P40225 | 3/20 | 0.97 |
| ▸ | TSHR | P16473 | 3/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29734979 | 1.00 | CYP3A4 (1.00) | CYP3A4TP53MEN1KMT2APMP22 | |
| Hydrochloric Acid SCHEMBL30603259 | 1.00 | CYP3A4 (1.00) | CYP3A4TP53MEN1KMT2APMP22 | |
| Hydrochloric Acid SCHEMBL30165585 | 1.00 | CYP3A4 (1.00) | CYP3A4TP53MEN1KMT2APMP22 | |
| Hydrochloric Acid SCHEMBL9895302 | 1.00 | CYP3A4 (1.00) | CYP3A4TP53MEN1KMT2APMP22 | |
| SCHEMBL12648358 | 0.99 | CYP3A4 (1.00) | CYP3A4TP53MEN1KMT2APMP22 | |
| SCHEMBL166960 | 0.99 | CYP3A4 (1.00) | CYP3A4TP53MEN1KMT2APMP22 | |
| Hydrochloric Acid SCHEMBL9895589 | 0.99 | MEN1 (1.00) | CYP3A4TP53MEN1KMT2APMP22 | |
| SCHEMBL9927435 | 0.99 | CYP3A4 (1.00) | CYP3A4TP53MEN1KMT2APMP22 | |
| SCHEMBL29695235 | 0.99 | CYP3A4 (1.00) | CYP3A4TP53MEN1KMT2APMP22 | |
| SCHEMBL1929636 | 0.97 | CYP3A4 (1.00) | CYP3A4TP53MEN1KMT2APMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2825173-B1 | CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES | CHILDRENS MEDICAL CENTER (US) | 2018-10-10 | — | — | EP | claimed |
| US-9827252-B2 | Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-11-28 | — | — | US | claimed |
| US-20160067261-A1 | SERCA INHIBITOR AND CALMODULIN ANTAGONIST COMBINATION | UNIVERSITAET DES SAARLANDES (DE) | 2016-03-10 | — | — | US | claimed |
| US-20150265627-A1 | CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-09-24 | — | — | US | claimed |
| EP-2825173-A2 | CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES | Children's Medical Center Corporation (US) | 2015-01-21 | — | — | EP | claimed |
| WO-2014173868-A1 | SERCA INHIBITOR AND CALMODULIN ANTAGONIST COMBINATION | UNIVERSITAET DES SAARLANDES (DE) | 2014-10-30 | — | — | WO | claimed |
| EP-2796137-A1 | SERCA inhibitor and Calmodulin antagonist combination | Universität des Saarlandes (DE) | 2014-10-29 | — | — | EP | claimed |
| WO-2013138101-A2 | CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2013-09-19 | — | — | WO | claimed |
| US-20110223177-A1 | TREATMENT OF FIBROTIC EYE DISORDERS | UNIVERSITY OF EAST ANGLIA (GB) | 2011-09-15 | — | — | US | claimed |
| EP-2323637-A1 | TREATMENT OF FIBROTIC EYE DISORDERS | University of East Anglia (GB) | 2011-05-25 | — | — | EP | claimed |
| EP-1996217-B1 | NOVEL ANTIBIOTIC COMPOSITIONS | CAMBRIDGE ENTPR LTD (GB) | 2010-11-10 | — | — | EP | claimed |
| WO-2010029350-A1 | TREATMENT OF FIBROTIC EYE DISORDERS | UNIVERSITY OF EAST ANGLIA (GB) | 2010-03-18 | — | — | WO | claimed |
| US-20080108115-A1 | ENHANCED PRODUCTION OF TAXOL AND TAXANES BY CELL CULTURES OF TAXUS SPECIES | DFB BIOTECH, INCORPORATED (US) | 2008-05-08 | — | — | US | claimed |
| US-7264951-B1 | Enhanced production of taxol and taxanes by cell cultures of Taxus species | PHYTON, INC. (US) | 2007-09-04 | — | — | US | claimed |
| WO-2007062862-A2 | USE OF CALMODULIN INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | LUDWIG MAXIMILIANS UNIVERSITÄT MÜNCHEN (DE) | 2007-06-07 | — | — | WO | claimed |
| EP-0771565-B1 | Angiogenesis inhibitor | SENJU PHARMA CO (JP) | 2003-01-02 | — | — | EP | claimed |
| US-20260027191-A1 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | UNIV ARIZONA (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4628100-A2 | ANTI-VIRAL COMPOUNDS AND METHODS FOR ADMINISTRATION THEREOF | Gregg, John Malcolm Hall (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-0608893-A1 | Inhibiting the development of tolerance to and/or dependence on an additive substance | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-08-03 | — | — | EP | disclosed |
| US-5321012-A | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance | VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL COLLEGE (US) | 1994-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067261-A1 | SERCA INHIBITOR AND CALMODULIN ANTAGONIST COMBINATION | ATP2A2, ATP2A1, ATP2A3 | SCN1A 506/4885SCN2A 95/4885SCN3A 238/4885 |
| US-20260027191-A1 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | DNMT3L, DNMT3A, DNMT1 | SCN1A 3120/4885SCN2A 3980/4885SCN3A 3245/4885 |
| US-20150265627-A1 | CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES | CALM1, RACK1, RRBP1 | SCN1A 824/4885SCN2A 1588/4885SCN3A 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.